Bicara Therapeutics

• United States

Sources: sec.gov

• A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  Phase 2, Recruiting, 160 people, Sep 8, 2026

• Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma

  Collaborator, Phase 2, Recruiting, 131 people, Apr 14, 2026

• FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  Phase 2/3, Recruiting, 650 people, Jan 23, 2025

• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  Phase 1, Recruiting, 473 people, Jun 12, 2020

Sources: clinicaltrials.gov

• Series C

  $165M, Dec 1, 2023

• Series B

  $30.2M, Nov 1, 2023

• Series B

  $40M, Sep 1, 2023

• Series B

  $38M, Mar 1, 2023

Sources: sec.gov